POPULARITY
Categories
103 episodes with annual meetings
111 episodes with annual meetings
87 episodes with annual meetings
85 episodes with annual meetings
54 episodes with annual meetings
66 episodes with annual meetings
56 episodes with annual meetings
53 episodes with annual meetings
49 episodes with annual meetings
38 episodes with annual meetings
39 episodes with annual meetings
25 episodes with annual meetings
29 episodes with annual meetings
56 episodes with annual meetings
29 episodes with annual meetings
19 episodes with annual meetings
23 episodes with annual meetings
26 episodes with annual meetings
23 episodes with annual meetings
37 episodes with annual meetings
25 episodes with annual meetings
30 episodes with annual meetings
19 episodes with annual meetings
14 episodes with annual meetings
17 episodes with annual meetings
13 episodes with annual meetings
16 episodes with annual meetings
16 episodes with annual meetings
15 episodes with annual meetings
15 episodes with annual meetings
13 episodes with annual meetings
14 episodes with annual meetings
16 episodes with annual meetings
11 episodes with annual meetings
10 episodes with annual meetings
11 episodes with annual meetings
19 episodes with annual meetings
15 episodes with annual meetings
11 episodes with annual meetings
13 episodes with annual meetings
8 episodes with annual meetings
9 episodes with annual meetings
17 episodes with annual meetings
10 episodes with annual meetings
9 episodes with annual meetings
14 episodes with annual meetings
9 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
9 episodes with annual meetings
10 episodes with annual meetings
9 episodes with annual meetings
8 episodes with annual meetings
14 episodes with annual meetings
12 episodes with annual meetings
7 episodes with annual meetings
9 episodes with annual meetings
10 episodes with annual meetings
7 episodes with annual meetings
4 episodes with annual meetings
11 episodes with annual meetings
14 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
7 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
8 episodes with annual meetings
9 episodes with annual meetings
7 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
9 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
7 episodes with annual meetings
6 episodes with annual meetings
8 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
9 episodes with annual meetings
13 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
12 episodes with annual meetings
8 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
3 episodes with annual meetings
5 episodes with annual meetings
6 episodes with annual meetings
14 episodes with annual meetings
5 episodes with annual meetings
7 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
7 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
10 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
3 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
20 episodes with annual meetings
3 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
12 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
7 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
3 episodes with annual meetings
7 episodes with annual meetings
2 episodes with annual meetings
6 episodes with annual meetings
2 episodes with annual meetings
8 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
10 episodes with annual meetings
3 episodes with annual meetings
8 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
9 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
12 episodes with annual meetings
3 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
10 episodes with annual meetings
2 episodes with annual meetings
4 episodes with annual meetings
60 episodes with annual meetings
3 episodes with annual meetings
In this episode, Shaji K. Kumar, MD, reviews key highlights from ASH 2025 in multiple myeloma (MM), focusing on emerging data for bispecific antibodies and CAR T-cell therapies across earlier and later lines of treatment. The discussion covers the following:MajesTEC-3: Results from the phase III study of teclistamab + daratumumab in R/R MM RedirecTT-1: Updated efficacy and safety of talquetamab + teclistamab in R/R MM and extramedullary diseaseCARTITUDE-4: Results following treatment with cilta-cel in patients with standard-risk cytogeneticsSTEM: Preliminary safety and efficacy data from the phase II study of cevostamab consolidation following BCMA-directed CAR T-cell therapyCAMMA1: Biomarker analyses from Arm B following cevostamab + pomalidomide and dexamethasone treatment in patients with R/R MMPresenter:Shaji K. Kumar, MDMark and Judy Mullins Professor of Hematological MalignanciesConsultant, Division of HematologyProfessor of MedicineResearch Chair, Division of HematologyMayo ClinicRochester, MinnesotaLink to full program: https://bit.ly/4995nFA Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
The Washington State Tree Fruit Association recently held their annual meeting with growers, packers, shippers and others from the industry gathering in Wenatchee.
"Lake City Chamber Chat" Ava LaRue talks with Heather Thomas, Executive Director for the Lake City Chamber of Commerce about their holiday hours this week and next, "Wake Up with Heather" moving to videos, Tour de Pepin registration will be opening in January, and a save-the-date for the Annual Meeting on March 20th, 2026.
Ohio Farm Bureau recently held its 107th Annual Meeting. Adam Sharp, executive vice president, joins the podcast to share key highlights and a look ahead to 2026. We also hear from Laramie Sandquist, associate vice president of Risk Management for Nationwide Agribusiness with tips on staying safe on the road during the holiday season.
Welcome to the Pharmacy Podcast Network's coverage of the NCPA 2025 Post Show! The NCPA annual conference is the trailblazer for community pharmacy, bringing together the pharmacy community. Our host Todd Eury, founder and CEO of the Pharmacy Podcast Network, took the microphone to the action right on the show floor capturing exclusive conversations with attendees, pharmacy students, keynote speakers, vendors, and more! Thank you NimbleRx for sponsoring this coverage of the NCPA Post Show! Visit https://www.nimblerx.com/
Featuring perspectives from Dr Terence Friedlander and Dr Rana R McKay, including the following topics: Introduction (0:00) Prostate Cancer (1:44) Urothelial Bladder Cancer (29:18) CME information and select publications
Dr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center and Dr Rana R McKay from the UC San Diego Moores Cancer Center summarize the treatment landscape for prostate and urothelial bladder cancer and discuss the implications of clinical findings recently presented at the ESMO Congress 2025.CME information and select publications here.
In this podcast episode, Jeremy S. Abramson, MD, MMSc, reviews data from select presentations in lymphomas at the ASH 2025 Annual Meeting and provides perspectives on the clinical implications of these data for patients with chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL), including:CLL17: randomized phase III trial of continuous ibrutinib vs fixed-duration venetoclax plus obinutuzumab or venetoclax plus ibrutinib for untreatedCLL BRUIN CLL-313: randomized phase III trial of pirtobrutinib vs BR for previously untreated patients with CLLBRUIN CLL-314: pirtobrutinib vs ibrutinib in treatment-naive and BTKi-naive R/R CLL/SLL EPCORE-FL-1: randomized phase III trial of epcoritamab with rituximab and lenalidomide vs rituximab and lenalidomide for R/R FLSTARGLO: 3-year follow-up data from the randomized phase III trial of glofitamab plus GemOx vs rituximab plus GemOx for patients with R/R DLBCLPresenter: Jeremy S. Abramson, MD, MMScProfessor of MedicineHarvard Medical SchoolDirector, Center for LymphomaMass General Brigham Cancer InsBoston, MassachusettsContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program:https://bit.ly/4aqMobZ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
As AI-generated music floods the market, the music industry faces unprecedented questions about creativity, copyright, and compensation. But behind every evolving technology and headline debate are the lawyers, often musicians themselves, who navigate the space where art and law converge. In this episode of Brand & New, guest host Rudy Gaines sits down with two leading intellectual property practitioners whose personal and professional lives are deeply connected to music: INTA Past President Mei-lan Stark, Executive Vice President and Chief Counsel for IP at NBCUniversal (USA) and Rick McMurtry, Founding Partner at M|C Law Group (USA). From childhood music lessons to high-stakes licensing negotiations, both guests share how their lifelong connection to music has shaped their careers, protecting creative works. Together, they trace the soundtrack of the industry's evolution, from the era of Napster to today's AI-driven soundscapes, exploring how innovation challenges what it means to be both creator and protector. This episode was recorded live during INTA's 2025 Annual Meeting in San Diego, California.Resources: About Mei-lan StarkAbout Rick McMurtryAbout Rudy GainesRelated Brand & New Episodes:The Beat of IP: A Conversation with The Opposition™ BandCertifying Human Music in the Age of AIINTA's 2026 Annual Meeting
The rise of artificial intelligence (AI) in music has sparked a new kind of identity crisis for artists and the industry alike. When anyone with a laptop can generate a song in seconds, how do listeners tell differentiate between human-created music and AI-generated music? In this episode of Brand & New, guest host Rudy Gaines talks with Paul McGrady, an intellectual property attorney and the co-founder of Humanable (USA), a certification platform that verifies when music is created entirely by human artists. Inspired by his daughter's journey in Nashville's music scene, Mr. McGrady shares how Humanable aims to protect musicians, preserve royalties, and help audiences reconnect with authentic artistry. Beyond the legal innovation, Mr. McGrady also discusses his Nashville alter ego, “Uncle Paul,” and his mission to spotlight independent musicians through social media and community advocacy. This episode was recorded live during INTA's 2025 Annual Meeting in San Diego, California. Resources: About Paul McGrady About Humanable About Rudy Gaines Related Brand & New Episodes:The Beat of IP: A Conversation with The Opposition™ BandWhen Music Meets IP: A Conversation with Mei-lan Stark and Rick McMurtryINTA's 2026 Annual Meeting
Send us a textDr. Edward Holland is a world-renowned leader in corneal transplantation and severe ocular surface disease, and is the Co-Founder of the Holland Foundation for Sight Restoration ( HFSR - https://www.hollandfoundationforsight.org/ ) is a 501(c)(3) nonprofit organization, dedicated to transforming the lives of individuals affected by these conditions, including limbal stem cell deficiency (LSCD) – a rare and devastating condition that can result in chronic pain, profound vision loss, and blindness.Through this HFSR initiative, Centers of Excellence (COEs) focused on the advanced sight restoration procedures of Ocular Surface Stem Cell Transplantation (OSST) are being launched across the country. As part of its mission, the foundation is also committed to broadening education and training so that more physicians nationwide can learn and implement The Cincinnati ProtocolTM for the management of these patients.Dr. Holland is also the Director of Cornea Services at Cincinnati Eye Institute ( https://www.cincinnatieye.com/doctors/edward-j-holland-m-d/ ) and Professor of Ophthalmology at the University of Cincinnati ( https://med.uc.edu/landing-pages/profile/Index/Pubs/hollanej ). Dr. Holland attended the Loyola-Stritch School of Medicine in Chicago and trained in Ophthalmology at the University of Minnesota. He completed a fellowship in cornea and external disease at the University of Iowa and then completed a second fellowship in ocular immunology at the National Eye Institute, National Institutes of Health in Bethesda, Maryland. Dr. Holland formerly served as the President for the American Society of Cataract and Refractive Surgery and served as the Program Chair for 12 years. Dr. Holland was a former member of the Board of Trustees for the American Academy of Ophthalmology and served as the Secretariat of the Annual Meeting. Dr. Holland has served as the Chair of the Eye Bank Association and was the former Chair of the Medical Advisory Board as well as a longtime member of the Board of Directors. Robert Dempsey, MBA is also a Co-Founder of the Holland Foundation for Sight Restoration.Mr. Dempsey brings more than two decades of domestic and global experience in the ophthalmic space driving successful drug development, business transactions and commercialization. His widespread experience in Ophthalmology stems from diverse Leadership roles across Commercial, Business Development, Medical Affairs and Venture Backed Startups. He brings deep relationships with Key Opinion Leaders and comprehensive knowledge of the ophthalmic ecosystem. Most recently, Mr. Dempsey served as the Chief Executive Officer for AsclepiX Therapeutics, following his CEO role at TearClear accelerating business and commercial strategies which led to several value inflection points and positive FDA engagements. Mr. Dempsey holds a Master's in Business Administration and a Bachelor of Science in healthcare marketing from Northeastern University in Boston, Massachusetts.Important Episode Link - Holland Foundation for Sight Restoration Launches Light After Darkness Fundraising Campaign - https://www.globenewswire.com/news-release/2025/10/22/3171067/0/en/Holland-Foundation-for-Sight-Restoration-Launches-Light-After-Darkness-Fundraising-Campaign.html#EdwardHolland #RobertDempsey #HollandFoundationForSightRestoration #OcularSurfaceStemCellTransplantation #Ophthalmology #LightAfterDarkness #Cornea #LimbalStemCell #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #STEM #Innovation #Technology #Science #ResearchSupport the show
Recorded live at the NCLifeSci 2025 Annual Meeting, Heather and Lauren sit down with Andrea Conner, Ecosystem Development Director for First Flight Venture Center, North Carolina's original science-based technology incubator. Andrea shares how First Flight helps high-science, deep-tech startups take flight through wraparound programs, lab space, and commercialization support. We also get insight into tackling funding challenges and the importance of collaboration across the RTP. Tune in for an inspiring conversation about innovation, entrepreneurship, and building a thriving life sciences community in North Carolina!
Boardroom On?! The Boardroom returns for a surprise December 2025 episode where we recap our overall thoughts on Nintendo this year and much more.Follow us on BlueSky:ToadstoolBoardroom | https://bsky.app/profile/toadstoolboa...Logan Plant | https://bsky.app/profile/loganjplant....Justin Koreis | https://bsky.app/profile/koreis.bsky....Chris Shriver | https://bsky.app/profile/shrives93.bs...Join Our Discord: / discord
In this episode, Hanny Al-Samkari, MD, gives his thoughts on 5 key presentations from ASH 2025, and provides perspectives on the clinical implications of these data for patients with nonmalignant hematologic disorders such as ITP and vWD, including: LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase III trial of ianalumab plus eltrombopag vs placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatmentAbstract 844: Secondary analysis results from VAYHIT3, a phase II study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least 2 lines of therapyAbstract 5: Deciphering the dilemma: intravenous (IV) iron use in iron deficiency anemia during acute infectionsAbstract 308: Subcutaneous, every-4-week maintenance dosing of a novel protein S antibody is well tolerated and substantially reduces bleeding rates: results from a phase I/II multidose study of VGA039 in patients with von Willebrand diseaseAbstract 841: Immune thrombocytopenia in patients treated with immune checkpoint inhibitorsPresenter:Hanny Al-Samkari, MDThe Peggy S. Blitz Endowed Chair in Hematology/OncologyCo-Director, Hereditary Hemorrhagic Telangiectasia Center of ExcellenceMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program:https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Despite huge environmnental challenges, Sylvia Earle believes there is not better time in history to be alive. Now 90, the pioneering ocean explorer has this message of hope for humanity. Links: Friends of Ocean Action: https://www.weforum.org/friends-of-ocean-action/ Mission Blue: https://missionblue.org/ Follow the World Economic Forum's Annual Meeting 2026 on the website wef.ch/wef26 and across social media using the hashtag #WEF26 Related podcasts: Ocean: how David Attenborough's new film will transform how you see Earth: https://www.weforum.org/podcasts/radio-davos/episodes/ocean-david-attenborough-colin-butfield/ Humans rely on the ocean. Here's how both can thrive: https://www.weforum.org/podcasts/radio-davos/episodes/ocean-marine-prosperity-areas/ Remembering Jane Goodall and her legacy of hope: https://www.weforum.org/podcasts/meet-the-leader/episodes/remembering-jane-goodall-leadership-lessons/ What my record 102-hour saltwater swim taught me about the ocean: https://www.weforum.org/podcasts/radio-davos/episodes/ocean-action-mediterranean-swim-noam-yaron/ Talks on creating a "Paris Treaty for plastics" just stalled - here's why, and what happens next: https://www.weforum.org/podcasts/radio-davos/episodes/plastics-treaty-inc-gpap/ Check out all our podcasts on wef.ch/podcasts: YouTube: https://www.youtube.com/@wef Radio Davos - subscribe: https://pod.link/1504682164 Meet the Leader - subscribe: https://pod.link/1534915560 Agenda Dialogues - subscribe: https://pod.link/1574956552 Join the World Economic Forum Podcast Club: https://www.facebook.com/groups/wefpodcastclub
In this podcast episode, Amir T. Fathi, MD, reviews data from select presentations in leukemias at the ASH 2025 Annual Meeting, and provides perspectives on the clinical implications of these data for patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), including:Abstract 6: Phase II PARADIGM trial of azacitidine and venetoclax vs conventional intensive chemotherapy for fit patients with newly diagnosed AMLAbstract 47: Phase I/II SAVE trial of revumenib plus decitabine/cedazuridine and venetoclax in the cohort of patients with newly diagnosed AMLAbstract 766: Phase Ib KOMET-007 trial of ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-mutant AMLAbstract 654: Phase I/II VICEROY trial of venetoclax and azacitidine + gilteritinib in patients with newly diagnosed FLT3-mutated AML ineligible for intensive induction chemotherapyAbstract 903: 3-Yr Update of the phase II FASCINATION trial of asciminib and conventional BCR::ABL1 inhibitors in newly diagnosed CMLAbstract 906: Phase II ASC2ESCALATE trial of asciminib in patients with chronic-phase CML after 1 prior TKIPresenter:Amir T. Fathi, MDDirector, Leukemia ProgramMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program:https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
This special episode was recorded just before the 43rd Annual Meeting of the WHO Programme for International Drug Monitoring wrapped up in Cairo, Egypt. Held from 27 to 29 October 2025, the meeting brought together representatives from more than 80 member states, along with senior experts and regulatory leaders from WHO headquarters and regional offices. Discussions focused on strengthening pharmacovigilance for women of childbearing age and children, in light of WHO's newly finalised Global Smart Pharmacovigilance Strategy. In this episode, you'll hear an abridged interview with Shanthi Pal, WHO Pharmacovigilance Team Lead, as she unpacks the new strategy and what it means for countries.Want to know more?Read WHO's “Global smart pharmacovigilance strategy” (Geneva: World Health Organization; 2025). Explore WHO's work on pharmacovigilance through the Programme for International Drug Monitoring (PIDM) and the WHO Pharmacovigilance Team.Learn more about regulatory systems strengthening and the WHO Global Benchmarking Tool (GBT) for medicines and vaccines.Discover the WHO network for regulatory systems strengthening – the Coalition of Interested Parties (CIP), of which UMC is a member.Visit the UMC website to find out more about the WHO PIDM and UMC's role in it. Join the conversation on social mediaFollow us on Facebook, LinkedIn, X, or Bluesky and share your thoughts about the show with the hashtag #DrugSafetyMatters.Got a story to share?We're always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!About UMCRead more about Uppsala Monitoring Centre and how we promote safer use of medicines and vaccines for everyone everywhere.
Recorded live at the NCLifeSci 2025 Annual Meeting, Marcel Frenkel, co-founder and CEO of Ten63 Therapeutics, joins hosts Heather Matthews and Lauren DeMoss for an exciting conversation about the future of drug discovery. Marcel shares how Ten63 is using advanced AI and computational tools to take on one of the hardest problems in medicine: the 80% of the human genome considered “undruggable.” By creating groundbreaking therapeutics and redefining what's possible for patients, Ten63 is opening the door to new treatments for cancer and rare diseases like Ewing sarcoma. Marcel explains how their approach could transform drug discovery, speed up development, and bring hope to patients who currently have no options. Listen now!
Today on the Digging in Podcast. We are joined by Laura Campbell, a Conservation & Regulatory Specialist for the Michigan Farm Bureau. Laura recently joined Missouri Farm Bureau at our Annual Meeting to talk about PFAS ‘Forever Chemicals' and how Michigan is addressing the challenge alongside the Michigan Farm Bureau. She joins us to highlight these conversations and detail the significant challenge farmers and communities face. Subscribe wherever you listen to podcasts to have Digging In sent directly to your smart device each time it's released! Host: Janet Adkison, Missouri Farm Bureau Director of Public Affairs Guest: Laura Campbell, Michigan Farm Bureau Conservation & Regulatory Specialist Producer: Jacob King, Missouri Farm Bureau Video & Audio Media Specialist
Recorded live at the NCLifeSci 2025 Annual Meeting, hosts Heather Matthews and Lauren DeMoss chat with Dr. Juliana Blum, CEO of BioAesthetics, a biomaterials company pioneering next-generation acellular grafts for tissue regeneration. Dr. Blum shares how her team is developing grafts that not only integrate into damaged tissue but also deliver embedded therapeutics to improve healing, reduce infection, and shorten recovery times for patients with burns, surgical wounds, and chronic ulcers. We also hear about her passion for startups, lessons learned from co-founding Humacyte, and why North Carolina is an ideal hub for biotech innovation. Tune in for a great episode!
This bonus episode of DermSurgery Digest features interviews recorded live at the 2025 ASDS Annual Meeting to provide the top pearls, insights and takeaways from the premier dermatologic surgery meeting of the year, held in Chicago, IL, on Nov. 13-16, 2025. The practice management, surgical oncology and reconstruction sessions discussed, and the contributors featured are: Knots and Bots: Dermatologic Surgery in the Era of AI featuring Drs. Daniel Schlessinger and Kyle LauckBeyond the Textbook: Controversies in Cutaneous Oncology and Dermatologic Surgery featuring Drs. Jordan Lim, David Carr and Kathryn ShahwanUnlocking the Job Search: Tips for Residents and Early Career Physicians featuring Drs. Mona Sadeghpour and Yssra SolimanSkin Substitute Alternatives for Recalcitrant Postoperative Wounds featuring Drs. Tara Jennings and Ally-Khan SomaniAdvanced Reconstruction featuring Drs. Tara Jennings and Naomi Lawrence This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery.Cosmetic dermatologic surgery sessions are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.
This bonus episode of DermSurgery Digest features interviews recorded live at the 2025 ASDS Annual Meeting to provide the top pearls, insights and takeaways from the premier dermatologic surgery meeting of the year, held in Chicago, IL, on Nov. 13-16, 2025. The cosmetic dermatologic surgery sessions discussed, and the contributors featured are: Integrating Cosmetic Surgery into Your Practice featuring Drs. Shawn Allen and Kyle LauckFat Grafting: New Discoveries and New Techniques featuring Drs. Lisa Donofrio and Megan McCleanASDS Glam Slam featuring Drs. Jamie Hu and Kyle LauckGLP-1: From Prescribing to Managing Volume Loss featuring Drs. Kavita Mariwalla and Sydney ProfferLower Face Cosmesis featuring Drs. Jean Carruthers and Ardalan MinokadehMaking the Most of Your Laser Settings featuring Drs. Paul Friedman and Pooja RambhiaNeuromodulators – The Cutting Edge featuring Drs. Deirdre Hooper, Rachel Pritzker and Sydney ProfferASDS Cosmetics Oral Abstract featuring Drs. Kyle Lauck, Aman Nihal and Nathalia Simonetti This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery.Practice management, surgical oncology and reconstruction sessions are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.
Professor Terlaky is the director of the Quantum Computing and Optimization Laboratory (QCOL). He served as the Chair of the Department of Industrial and Systems Engineering, Lehigh University, 2008 – 2017. Prior to his appointment at Lehigh U., Prof. Terlaky has taught at Eötvös U., Budapest, Hungary; Delft University of Technology, Delft, Netherlands; McMaster U., ON, Canada. At McMaster he also served as the founding Director of the School of Computational Engineering and Science. Prof. Terlaky has published four books, edited over ten books and journal special issues and published over 220 research papers. Topics include theoretical and algorithmic foundations of operations research (e.g., invention of the criss-cross method), design and analysis of large classes of interior point methods, computational optimization, worst case examples of the central path, nuclear reactor core reloading optimization, oil refinery and VLSI design optimization and robust radiation therapy treatment optimization. Further, his research interest includes high performance optimization methods, optimization modeling, optimization problems in engineering sciences, and Quantum Computing Optimization. Prof. Terlaky is Founding Editor-in-Chief of the journal, Optimization and Engineering, and Editor-in-Chief of the Journal of Optimization Theory and Applications . He has served as associate editor of ten journals and has served as conference chair, conference organizer, and distinguished invited speaker at conferences all over the world. He was general Chair of the INFORMS 2015 Annual Meeting, a former Chair of INFORMS' Optimization Society, Chair of the ICCOPT Steering Committee of the Mathematical Optimization Society, Chair of the SIAM Activity Groupon Optimization. He received: the MITACS Mentorship Award for his distinguished Ph.D. student supervisory record; the Egerváry Award of the Hungarian Operations Research Society; the Award of Merit of the Canadian Operations Research Society; The Wagner Prize of INFORMS; The Outstanding Innovation in Service Science Engineering Award of IISE. Prof. Terlaky is Fellow of the Fields Institute, Fellow of INFORMS, Fellow of SIAM, Fellow of IFORS, and Fellow of the Canadian Academy of Engineering.
Send us a textJoin our host, Dr. Stephanie Ihnow, in a conversation with the Russell A. Hibbs, John H. Moe, and Louis A. Goldstein Award Winners as they talk about their research. Don't miss this opportunity to hear from some of the brightest minds in the field!Congratulations to:The 2025 Hibbs Award For Best Clinical Research Paper was presented To Wait to Operate: Surgery Demonstrated No Pulmonary Benefit Compared to Non-Operative Treatment in EOS Patients by Amy L. McIntosh, MD; Charles E. Johnston, MD; Tiffany Thompson, BS; JP Rathbun, BS; Chan-Hee Jo, PhD; Karina A. Zapata, PhD, PT, DPTThe 2025 Hibbs Award For Best Basic Science/Translational Research Paper was presented to Spinal Growth Regulation by Interfering Chondrocytes Function in Growth Plate is a Potential Treating Method for Scoliosis: Preliminary Study in Piglets by Zhaoquan Zhang, MD; Zhibo Song, MD; Yingsong Wang, MD; Zhi Zhao, MD; Ni Bi, MD; Jingming Xie, MD; Tao Li, MD; Li Zhang, MD; Ying Zhang, MD; Zhiyue Shi, MDThe 2025 John H. Moe Award For Best Basic Science/Translational Research Poster was presented to Collagen X Biomarker (Cxm) is Predictive of Growth Cessation in Idiopathic Scoliosis by Michelle C. Welborn, MD; Asal Roudbari, BS; Reza Zandehshahvar, PhD; Pascal Van Hentenryck, PhD; Amer F. Samdani, MD; Robert H. Cho, MD; Joseph D. Stone, MD; Selina C. Poon, MD; Vishwas R. Talwalkar, MD; Michal Szczodry, MD; Purnendu Gupta, MD; James O. Sanders, MD; Susan Sienko, PhDThe 2025 Louis A. Goldstein Award For Best Clinical Research Poster was presented to Growth Modulation Does Not Improve 3D Axial Rotation After VBT: A 3D Multi-Center Analysis by Melanie E. Boeyer, PhD; Samuel Hawkins, BS; Vladislav Husyev, BS; Stefan Parent, MD, PhD; Peter O. Newton, MD; Burt Yaszay, MD; Harms Study Group; Dan Hoernschemeyer, MD.*The Scoliosis Research Society (SRS) podcast is aimed at delivering the most current and trusted information to clinicians that care for patients with scoliosis and other spinal conditions. From news in the world of spinal conditions, to discussions with thought leaders in the field, we aim to provide up-to-date, quality information that will impact the daily practice of spinal conditions.
Host Dr. Joe Patterson sits down with Drs. Michael Sutherland, Bryant Oliphant, and Jennifer Hagen to talk about the American College of Surgeons Committee on Trauma and how orthopedic trauma surgeons can get involved and benefit from the organization in daily practice. Live from the OTA 2025 Annual Meeting. For more information and to become an ACS member, click here. For additional educational resources visit OTA.org
Sarah talks to Zack about Tuesday's NextGen event at Peat's Cider Social, plus ribbon cuttings, "Brew" Year's Eve in Baroda, and nominations for the Chamber Breakfast & Annual Meeting. Get details at SMRChamber.com!See omnystudio.com/listener for privacy information.
Featuring perspectives from Prof Giuseppe Curigliano and Dr Priyanka Sharma, including the following topics: HER2-Positive Breast Cancer (0:00) Hormone Receptor-Positive Breast Cancer (18:16) Triple-Negative Breast Cancer (1:05:23) CME information and select publications
Recorded live at the NCLifeSci 2025 Annual Meeting, hosts Heather Matthews and Seth Hudson welcome episode guest Ron Phillips, Senior Vice President of Policy for the Animal Health Institute. Representing companies that develop medicines for pets and livestock, Ron shares insights on the similarities and differences between human and animal drug development as well as why innovation and regulatory modernization are critical for the future of animal health. The conversation also explores challenges in clinical trials, consumer acceptance, and the growing importance of the One Health concept, which links human, animal, and environmental health. Tune in now!
Prof Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss the implications of clinical findings in breast cancer recently presented at the 2025 ESMO Annual Meeting. CME information and select publications here.
Katie Laleman joined Wake Up Tri-Counties to talk about awards at the annual Illinois Farm Bureau meeting, Bushels for Hunger, an international trip for 2026, a "Cram A Ford" update, and a farm succession workshop in February. The Henry County Farm Bureau is gearing up for a series of significant events. Representatives attended the Illinois Farm Bureau annual meeting in Chicago, where county awards and policy changes will be spotlighted. With state officer elections and key policy decisions on the agenda, members are also looking forward to celebrating local achievements. Young leaders from Henry County will compete in discussion meets, and Kate Huffman was recognized for her agricultural achievements. Harvest season is winding down, but farmers are reminded to drive safely, especially when transporting equipment and crops. The Bushels for Hunger campaign remains open for grain donations through December 31, supporting local food pantries. Members interested in an Ireland trip can attend an informational meeting on November 20th. A farm succession planning workshop takes place on February 20th at Lavender Crest Winery—advance registration required.
We are excited to welcome our guest on this episode, Danielle Sparks. Danielle is our 2025-2026 ASHT president. During her incoming presidential address at the Annual Meeting, Danielle challenged us to consider how we can be advocates for our specialty and our patients. There are many challenges we face daily, but she shares with us how small, atomic changes can have a lasting effect. Guest Bio:Danielle Sparks, DHS, MOT, OTR, CHT is a highly experienced occupational therapist and Certified Hand Therapist with a strong clinical background in upper extremity rehabilitation. With over 15 years in the field, Danielle has spent her career at the Indiana Hand to Shoulder Center, where she has served as the Director of Therapy since 2017. Danielle graduated from Indiana University Bloomington in 2007 with a Biology degree. She earned a Master of Occupational Therapy in 2009 and then post professionally a Doctorate of Health Science in 2017, both from the University of Indianapolis. Danielle earned her Certified Hand Therapist credential in 2015. Passionate about advocacy and legislative and regulatory aspects of practicing hand therapy, Danielle has been a member of the American Society of Hand Therapists since 2012 and has been a volunteer in the Practice Division since 2017, serving as the chair from 2020-2023 and currently is serving in the ASHT Presidential line 2023-2027. Currently, Danielle is the current President for ASHT. Danielle enjoys attending courses related to upper extremity rehabilitation and the opportunity to learn from and interact with colleagues. When not involved in work related activities, Danielle enjoys traveling, kayaking, hiking, golfing, and spending time with family and her two German Shepherds. The views and opinions expressed in the Hands in Motion podcast are those of the guests and do not necessarily reflect the official policy or position of ASHT. Appearance on the podcast does not imply endorsement of any products, services or viewpoints discussed.
Rusty Halvorson and Sarah Heinrich share some of the week's top stories in agriculture.See omnystudio.com/listener for privacy information.
Featuring an interview with Dr Priyanka Sharma, including the following topics: Endocrine therapy for hormone receptor-positive, HER2-negative high-risk localized breast cancer (0:00) Johnston SR et al. monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC). ESMO 2025;Abstract LBA13. Durvalumab in combination with neoadjuvant chemotherapy for localized triple-negative breast cancer (TNBC) (3:25) Loibl S et al. Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC) – Long-term analysis from the GeparNuevo trial. ESMO 2025;Abstract 292MO. Efficacy and safety findings with TROP2-directed antibody-drug conjugates for metastatic TNBC (5:11) Cortés JC et al. Primary results from ASCENT-03: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i). ESMO 2025;Abstract LBA20. de Azambuja E et al. Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in patients (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) in the phase III ASCENT-04/KEYNOTE-D19 study. ESMO 2025;Abstract LBA22. Dent R et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial. ESMO 2025;Abstract LBA21. CME information and select publications
Many leaders in the healthcare system and academic medicine, by default, manage their day through transactional leadership. However, as we learn in this week's episode of the Faculty Factory Podcast, there may be a better way. We are thrilled to welcome Martin Zeier, MD, visiting us from Germany this week on the podcast to discuss transformational leadership. Dr. Zeier leads the Division of Nephrology at the University of Heidelberg in Germany. He recently traveled to the United States and attended the Annual Meeting of the American Society of Nephrology, which took place in Houston. You can learn more about the University of Heidelberg here: https://www.nierenzentrum-heidelberg.com Transformational leadership helps us build trust between one another, which is one of its core principles and plays a key role in mentoring the next generation of leaders. This leadership style can strengthen our teams to advance our institutions and the missions we serve. It also challenges us to lead through intellectual stimulation, because academic professionals are not at their best without the opportunity for growth. “I have always been curious about how I could build and enhance teams and how I could improve as a medical professional and leader,” Dr. Zeier stated at the interview's outset. His own intellectual curiosity over the years served as an impetus for him to study organizational psychology in his advanced studies, as he also shared with us. Learn more about the Faculty Factory: https://facultyfactory.org/
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here.
Featuring an interview with Dr Priyanka Sharma, including the following topics: Patient-reported outcomes from the SERENA-6 trial of camizestrant with a CDK4/6 inhibitor for patients with HR-positive, HER2-negative advanced breast cancer and ESR1 mutations emerging during first-line endocrine-based therapy (0:00) Mayer E et al. Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC). ESMO 2025;Abstract 486MO. Imlunestrant and abemaciclib versus fulvestrant and abemaciclib for ER-positive, HER2-negative advanced breast cancer: An indirect treatment comparison of 3 Phase III trials (3:00) Bidard FC et al. Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): An indirect treatment comparison (ITC) of three phase 3 trials. ESMO 2025;Abstract 496P . Giredestrant in the treatment of ER-positive, HER2-negative breast cancer: The Phase III evERA Breast Cancer and EMPRESS trials (5:39) Mayer E et al. Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial. ESMO 2025;Abstract LBA16. Llombart-Cussac A et al. Preoperative window-of-opportunity study with giredestrant or tamoxifen (tam) in premenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) and Ki67≥10% early breast cancer (EBC): The EMPRESS study. ESMO 2025;Abstract 294MO. Capivasertib/fulvestrant as first- and second-line endocrine-based therapy for PIK3CA/AKT1/PTEN-altered HR-positive advanced breast cancer in the CAPItello-291 trial and gedatolisib/fulvestrant with or without palbociclib for HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer in the VIKTORIA-1 trial.(10:25) Rugo HS et al. Capivasertib plus fulvestrant as first and second-line endocrine-based therapy in PIK3CA/AKT1/PTEN-altered hormone receptor-positive advanced breast cancer: Subgroup analysis from the phase 3 CAPItello-291 trial. ESMO 2025;Abstract 526P. Hurvitz SA et al. Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/ HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1. ESMO 2025;Abstract LBA17. CME information and select publications
This episode, Heather and Seth record at the NCLifeSci 2025 Annual Meeting with Tom Croce, Vice President of Global Patient Advocacy and Engagement at Jazz Pharmaceuticals. Tom shares how his team integrates patient perspectives across the entire drug development and commercialization process, and why “patient centricity” is transforming the pharmaceutical industry. We explore the growing role of patient input in clinical trials, the future of advocacy-driven innovation, and more. Tune in for an insightful discussion on building better treatments by listening to the people who need them most.
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here.
*Texas Farm Bureau's Annual Meeting is coming up. *An equine virus outbreak has horse owners concerned.*Finding information on the federal government's efforts to combat New World Screwworms just got a lot easier.*The Amarillo Farm and Ranch Show is just around the corner.*Goat owners should look for minerals that are palatable and affordable.
Stephanie Larson and Mikie McDonnell encourage you to attend the Society for Range Management's flagship event in Monterey, California to kick off the International Year of Rangelands and Pastoralists. Listen to learn about location, conference themes, tour options, and plenary sessions. Go to the episode page at https://artofrange.com/episodes/aor-171-celebrating-global-rangelands-pastoralism-srms-2026-annual-meeting for conference website links and a transcript of this conversation.
Featuring an interview with Dr Priyanka Sharma, including the following topics: T-DXd versus trastuzumab emtansine for high-risk HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy: Interim analysis of the DESTINY-Breast05 trial (0:00) Geyer C et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05. ESMO 2025;Abstract LBA1. DESTINY-Breast11 trial: Neoadjuvant T-DXd alone or followed by paclitaxel/trastuzumab/pertuzumab for high-risk HER2-positive localized breast cancer (5:42) Harbeck N et al. DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC). ESMO 2025;Abstract 291O. Trastuzumab deruxtecan (T-DXd) and pertuzumab versus a taxane, trastuzumab and pertuzumab for HER2-positive advanced or metastatic breast cancer: Additional analyses of the DESTINY-Breast09 trial (10:00) Loibl S et al. Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest. ESMO 2025;Abstract LBA18. CME information and select publications
Episode 40- NASPGHAN/APGNN/CPNP Annual Meeting RecapIn this episode of Nutrition Pearls: the Podcast, host Jen Smith asks members of the CPNP executive committee questions about their experiences and learnings at the annual meeting.Nutrition Pearls is supported by an educational grant from Mead Johnson Nutrition.Produced by: Corey IrwinNASPGHAN - Council for Pediatric Nutrition Professionalscpnp@naspghan.org
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here.
Dr. Joe Patterson hosts a conversation with Drs. Ashley Levack, Sean Campbell, and Joshua Gary about managing busy orthopaedic practices and balancing family needs and obligations throughout the seasons of professional and personal life. Live from the OTA 2025 Annual Meeting. For additional educational resources visit OTA.org
The Army needs innovative and efficient solutions to problems. At the Association of the United States Army's Annual Meeting and Exposition in Washington, D.C., Innovation Officer at the Army's 3rd Infantry Division's Marne Innovation Center (MIC) Capt. Brendan Shutt explained how the Army's grassroots innovation model is transforming problem-solving. The center embeds innovation directly into training environments, sourcing problems from soldiers in real time and involves warfighters firsthand in innovation. He said its soldier-driven, agile approach offers a compelling blueprint for future battlefield innovation and efficiency. Shutt described challenges with scaling solutions across the Army, but said partnerships with academia provide fresh perspectives, technical bandwidth and can support more complex projects involving AI and autonomous systems.
Along with our usual time for music and prayer, we're hosting our annual meeting (instead of a message) — a time for updates and questions about the financial side of running our church. All are welcome, whether you consider yourself a stakeholder in BLC or you're just curious how this church does “family conversations”. Join our live chat! https://discord.gg/MNXJSM8New here? http://brownlinechurch.org/connectResources http://brownlinechurch.org/resources Donate http://brownlinechurch.org/donate
Along with our usual time for music and prayer, we're hosting our annual meeting (instead of a message) — a time for updates and questions about the financial side of running our church. All are welcome, whether you consider yourself a stakeholder in BLC or you're just curious how this church does “family conversations”. Join our live chat! https://discord.gg/MNXJSM8New here? http://brownlinechurch.org/connectResources http://brownlinechurch.org/resources Donate http://brownlinechurch.org/donate
This special episode brings you inside the 79th Annual Meeting of the American Academy of Cerebral Palsy and Developmental Medicine (AACPDM), held in New Orleans, October 15–18, 2025. Join host Tyler McDonald from the University of South Alabama as he attends his first AACPDM meeting and highlights the moments, conversations, and clinical insights most relevant to pediatric orthopedic surgeons. Hosted, recorded, and produced by Tyler McDonald. Intro music by A. A. Aalto. Additional royalty-free music provided by Pixabay. Link to Jon David's diagnostic matrix for gait analysis: https://journals.lww.com/jbjsjournal/pages/articleviewer.aspx?year=2003&issue=11000&article=00028&type=Citation
Welcome to the Pharmacy Podcast Network's coverage of the NCPA 2025 Post Show! The NCPA annual conference is the trailblazer for community pharmacy, bringing together the pharmacy community. Our host Todd Eury, founder and CEO of the Pharmacy Podcast Network, took the microphone to the action right on the show floor capturing exclusive conversations with attendees, pharmacy students, keynote speakers, vendors, and more! Thank you YARAL Pharma for sponsoring this coverage of the NCPA Post Show! Visit https://yaralpharma.com/
Tim and Tyler talk about Tyler's experience at the Western Growers Annual Meeting this week and recap the "Shark Tank" event from the show. — This episode is presented by Corteva R&D. — Links Western Growers - https://www.wga.com TRIC Robotics - https://www.tricrobotics.com Drift Sense - https://drift-sense.com Lumo - https://lumo.ag
© 2020-2025 Ivy Podcast Discovery LLC
